RUNX2 and neoplasm: Indeed, both SOX9 and RUNX2 can act as oncogenes or tumor suppressors in a context-dependent manner—their expression is characteristic for cancer stem-like cells (CSCs) and they are involved in metastasis and chemoresistance [34,35].